MSK
Search
- Page Path
- HOME > Search
Review
- Recent advances in the development of β-lactamase inhibitors
- Shivakumar S. Jalde , Hyun Kyung Choi
- J. Microbiol. 2020;58(8):633-647. Published online July 27, 2020
- DOI: https://doi.org/10.1007/s12275-020-0285-z
- 16 View
- 1 Download
- 20 Citations
-
Abstract
- β-Lactam antibiotics are the most commonly prescribed antibiotics worldwide; however, antimicrobial resistance (AMR) is a global challenge. The β-lactam resistance in Gram-negative bacteria is due to the production of β-lactamases, including extended-spectrum β-lactamases, metallo-β-lactamases, and carbapenem-hydrolyzing class D β-lactamases. To restore the efficacy of BLAs, the most successful strategy is to use them in combination with β-lactamase inhibitors (BLI). Here we review the medically relevant β-lactamase families and penicillins, diazabicyclooctanes, boronic acids, and novel chemical scaffold-based BLIs, in particular approved and under clinical development.
First
Prev
TOP
